The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Understanding the Benefits and Risks of Pharmaceuticals: Workshop Summary
IOM (Institute of Medicine). 2006. Valuing Health for Regulatory Cost-Effectiveness Analysis. Washington, DC: The National Academies Press.
Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E, Burdick E, Seger DL, Vliet MV, Bates DW. 1998. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. Journal of the American Medical Informatics Association 5:305–314.
National Research Council. 1983. Risk Assessment in the Federal Government: Managing theProcess. Washington, DC: National Academy Press.
National Research Council. 1999. Health Effects of Exposure to Radon, BEIR VI. Washington, DC: National Academy Press.
Nease Jr. RF, Kneeland T, O’Connor GT, Sumner W, Lumpkins C, Pryor D, Sox HC. 1995. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. Journal of the American Medical Association 273(15):1185–1190.
OMB (Office of Management and Budget). 2005. Validating Regulatory Analysis: 2005 Report to Congress on the Costs and Benefits of Federal Regulations and Unfunded Mandates on State, Local, and Tribal Entities. Washington, DC: OMB
Sheiner LB. 1997. Learning vs. confirming in clinical drug development. Clinical Pharmacologyand Therapeutics 61:275–291.
Spiegel BM, Targownik L, Dulai GS, Gralneck IM. 2003. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals ofInternal Medicine 138(1):795–806.
Stossel TP. 2005. Regulating academic-industrial research relationships—solving problems or stifling progress? New England Journal of Medicine 353:1060–1065.
Strom BL. 2006. How the U.S. drug safety system should be changed. Journal of the AmericanMedical Association 295:2072–2075.
Weinstein ND. 1999. What does it mean to understand a risk? Evaluating risk comprehension. Journal of the National Cancer Institute 25:15–20.
Woloshin S, Schwartz LM, Welch HG. 2004. The value of benefit data in direct-to-consumer drug ads. Health Affairs Suppl Web Exclusives: W4-234–W4-245.